John H . Farley

Department

Obstetrics & Gynecology (Phoenix)

Position

Professor

Books

• Emerging Therapeutic Targets in Ovarian Cancer
  Farley John, etal Discovery of Novel Targets [Book Chapter] 2011
• Cancer Treatment and Research
  Farley John, etal Novel Therapeutic Targets [Book Chapter] 2009
• Pathway Analysis for Drug Discovery
  Farley John, etal Whole‐Genome Expression Profiling of Papillary Serous Ovarian Cancer: Activated Pathways, Potential Targets, and Noise [Book Chapter] 2008

Publications

• Journal for immunotherapy of cancer
  Patel Sandip P, etal Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of D ual A nti-CTLA-4 and Anti-PD-1 blockade in R are T umors (DART) SWOG S1609 (Cohort 38)
  13:10, p. e013147 2025
• Cancer
  Lin Ken Y, etal Putting a spotlight on current chemotherapeutic options for recurrent ovarian clear cell carcinoma
  131:19, p. e70112 2025
• Gynecologic oncology
  Pothuri Bhavana, etal Identifying and breaking racial and ethnic barriers: Enhancing access and equity in the care of patients with gynecologic malignancies
  200, p. 76 - 77 2025
• Gynecologic oncology
  Pothuri Bhavana, etal Identifying and breaking barriers for the treatment of gynecologic malignancies within the lesbian, gay, bisexual, transgender, queer/questioning, intersex and/or asexual community
  200, p. 290 - 291 2025
• Gynecologic oncology reports
  Pothuri Bhavana, etal Identifying and breaking barriers: Addressing disparities in the care of patients with gynecologic cancers, p. 101799 2025
• Cancer
  Ebott Jasmine, etal Gender equity gap persists, addressing the root cause through the lens of gynecologic oncology: An evidenced-based review
  131:9, p. e35843 2025
• Gynecologic oncology
  Tumas Jordyn, etal Racial disparities in survival and molecular features among Black versus White patients with uterine serous carcinoma: An integrated study in real-world registries and legacy NRG Oncology/Gynecologic Oncology Group clinical trials
  190, p. S123 - S125 2024
• Gynecologic oncology
  Kopelman Zachary, etal Disease progression, survival, and molecular disparities among Black and White patients with endometrioid endometrial carcinoma in real-world registries and legacy NRG oncology phase III trials
  190, p. S34 - S35 2024
• Gynecologic oncology
  Kopelman Zachary A., etal Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials
  183, p. 103 - 114 2024
• Obstetrical & gynecological survey
  Girda Eugenia, etal Cervical Cancer Treatment Update: A Society of Gynecologic Oncology Clinical Practice Statement
  79:3, p. 159 - 160 2024
• Gynecologic oncology
  Kucera Calen W., etal Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors
  184, p. 224 - 235 2024
• Gynecologic oncology
  Winkler Stuart S, etal Racial, ethnic and country of origin disparities in aggressive endometrial cancer histologic subtypes
  184, p. 31 2024
• Gynecologic oncology
  Girda Eugenia, etal Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement
  179, p. 115 - 122 2023
• Journal of clinical oncology
  Arend Rebecca C., etal Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018), p. JCO2202915 - JCO2202915 2023
• Clin Cancer Res
  Grisham Rachel N, etal Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
  29:20, p. 4068 - 4075 2023
• Clinical cancer research
  Grisham Rachel N, etal Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer 2023
• Gynecologic oncology
  Kucera Calen, etal P21 Survival disparities between Non-Hispanic Blacks and Whites with cervical cancer are largely dominated by adenocarcinoma histology and explained by modifiable factors
  173, p. S20 - S21 2023
• Journal of minimally invasive gynecology
  Stewart Chelsea, etal Factors associated with inpatient narcotic medication usage after robotic assisted laparoscopy 2023
• Journal of geriatric oncology
  Moore Madison S., etal Robotic-assisted gynecologic surgery in an older population: A comparison study
  14:6, p. 101533 - 101533 2023
• JAMA network open
  Kucera Calen W, etal Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer
  6:4, p. e238437 - e238437 2023
• Gynecologic oncology reports
  Schink Julian, etal 36 Mutational landscape of low-grade serous carcinoma of the ovary
  44, p. S18 - S19 2022
• Gynecologic oncology reports
  Garg Ruchi, etal 6 Racial differences in the mutational landscape of serous endometrial cancer
  44, p. S3 - S4 2022
• Gynecologic oncology reports
  Garg Ruchi, etal 37 Therapeutic implications of mutations in high grade serous ovarian carcinoma when evaluated by race
  44, p. S19 - S19 2022
• Gynecologic oncology
  Sitler Collin, etal Do U.S. Screening Guidelines Contribute to Higher Stage and Worse Survival in our Youngest and Oldest Cervical Cancer Patients? (019)
  166, p. S14 - S15 2022
• Journal of clinical oncology
  Schink Julian C., etal Racial differences in the mutational landscape of serous endometrial cancer
  40:16_suppl, p. 5600 - 5600 2022
• Journal of clinical oncology
  Schink Julian C., etal Mutational landscape of low-grade serous carcinoma of the ovary
  40:16_suppl, p. 5578 - 5578 2022
• Journal of clinical oncology
  Garg Ruchi, etal Therapeutic implications of mutations in high grade serous ovarian carcinoma when evaluated by race
  40:16_suppl, p. e17590 - e17590 2022
• Gynecologic oncology
  Jokajtys Suzanne, etal P9 Mixed endometrial cancer a rare histology with the largest racial disparity in survival
  165, p. S9 - S10 2022
• Journal of clinical oncology
  Grisham Rachel N., etal Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC)
  39:15_suppl, p. 5519 - 5519 2021
• Gynecologic oncology
  Chase Dana M., etal Unwittingly biased: A note to gynecologic cancer providers
  160:3, p. 646 - 648 2021
• Gynecologic oncology
  Brown J., etal Feasibility of a platform trial in rare gynecologic cancers based on molecular analysis
  159, p. 144 - 145 2020
• Gynecologic oncology
  Crane E.K., etal Molecular profiling in a large cohort of gynecologic neuroendocrine tumors
  159, p. 262 - 262 2020
• Tewari Krishnansu S, etal Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study 2020
• Gynecologic oncology
  Tewari Krishnansu S., etal BEVACZIUMAB PLUS FOSBRETABULIN IN RECURRENT OVARIAN CANCER: OVERALL SURVIVAL AND EXPLORATORY ANALYSES OF A RANDOMIZED PHASE II NRG ONCOLOGY/GYNECOLOGIC ONCOLOGY GROUP STUDY
  159:1, p. 79 - 87 2020
• Journal of clinical oncology
  Brown Jubilee, etal Feasibility of a platform trial based on molecular analysis in rare gynecologic cancers
  37:15_suppl, p. e14585 - e14585 2019
• Gynecologic oncology
  Konstantinopoulos Panagiotis A., etal Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)
  150:1, p. 9 - 13 2018
• Gynecologic oncology
  Oliver Kate E., etal An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience
  147:2, p. 243 - 249 2017
• Gynecologic oncology
  Moreno A., etal Factors Associated with Increased Narcotic Usage after Undergoing Robotic Assisted Laparoscopy
  147:1, p. 203 - 203 2017
• Gynecologic oncology
  Barnes Dominique, etal Patient characteristics associated with obesity in an endometrial cancer patient: first steps towards the design of a weight loss intervention
  147:1, p. 215 - 215 2017
• Gynecologic oncology
  Barnes Dominique, etal Clinic-based Depression Screening in Gynecologic Oncology Patients using the Patient Health Questionnaires-2 (PHQ-2): are we identifying the highest risk patients?
  147:1, p. 215 - 215 2017
• Gynecologic oncology
  Vo E.H., etal Robotic-assisted Gynecologic Surgery in an Elderly Population: A Comparison Study
  147:1, p. 204 - 205 2017
• Hematological oncology
  Biasoli I., etal Treatment outcomes for Hodgkin's lymphoma patients aged 60 and older: A report from the Brazilian prospective Hodgkin's lymphoma registry
  35:S2, p. 308 - 309 2017
• European journal of gynaecological oncology
  Niu J., etal Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer
  38:1, p. 40 - 44 2017
• Gynecologic oncology research and practice
  Minion Lindsey E., etal Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study
  3:1, p. 4 - 4 2016
• Molecular cancer therapeutics
  Weiss Glen J., etal Abstract A50: Phase Ib/II study of pembrolizumab plus chemotherapy: Initial results of metastatic cancer patients
  14:12_Supplement_2, p. A50 - A50 2015
• Obstetrics and gynecology (New York. 1953)
  Chase Dana M, etal Disparities in Vulvar Cancer Reported by the National Cancer Database: Influence of Sociodemographic Factors
  126:4, p. 792 - 802 2015
• Clinical cancer research
  Ramos Pilar, etal Abstract POSTER-BIOL-1327: Small cell carcinoma of the ovary, hypercalcemic type displays frequent inactivating germline and somatic mutations in SMARCA4
  21:16_Supplement, p. POSTER-BIOL-1327 - POSTER-BIOL-1327 2015
• Journal of clinical oncology
  Niu Jiaxin, etal Platinum-gemcitabine-bevacizumab (PGA) for platinum-resistant/refractory recurrent ovarian cancer
  33:15_suppl, p. e16534 - e16534 2015
• Gynecologic oncology
  Shields K.M., etal Factors associated with low educational background in uterine cancer patients
  137, p. 123 - 123 2015
• International Journal of Gynecological Cancer
  Gourley C., etal Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas
  24:9 Suppl 3, p. S9 - 13 2014
• Cancer research (Chicago, Ill.)
  Ramos Pilar, etal Abstract LB-202: The rare, highly malignant small cell carcinoma of the ovary displays common inactivating germline and somatic mutations in the tumor suppressor SMARCA4
  74:19_Supplement, p. LB-202 - LB-202 2014
• Gynecologic oncology research and practice
  Foss Cassandra D, etal Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
  1:1, p. 4 - 4 2014
• Gynecologic oncology
  Oliver K.E., etal An evaluation of progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients with clear cell carcinoma vs serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group (GOG) experience
  133, p. 26 - 27 2014
• Gynecologic Oncology
  Miller Caela R., etal MEK1/2 inhibitors in the treatment of gynecologic malignancies
  133:1, p. 128 - 137 2014
• Rare diseases (Austin, Tex.)
  Ramos Pilar, etal Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
  2:1, p. e967148 - e967148 2014
• Supportive care in cancer
  Craig Christine D, etal Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment
  22:1, p. 279 - 287 2014
• Gynecologic oncology
  Craig C., etal The characteristics and associations of pelvic pain in gynecologic cancer patients: A single institution study
  131:1, p. 264 - 264 2013
• Gynecologic oncology
  Miller C., etal An evaluation of molecular markers that predict maximal surgical cytoreduction: A Gynecologic Oncology Group trial
  130:1, p. e20 - e20 2013
• Gynecologic oncology
  Craig C., etal Pelvic pain, quality of life (QOL), and exercise in gynecologic cancer patients: A single institution study
  130:1, p. e31 - e32 2013
• Gynecologic oncology
  Craig C., etal Therapeutic choices and outcomes in vulvar cancer cases reported by the National Cancer Database Registry
  130:1, p. e163 - e163 2013
• Journal of clinical oncology
  Farley John H., etal An evaluation of survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group experience
  31:15_suppl, p. 5534 - 5534 2013
• The lancet oncology
  Farley John, etal Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
  14:2, p. 134 - 140 2013
• Critical Reviews in Oncology/Hematology
  Monk Bradley J., etal Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
  86:2, p. 161 - 175 2013
• Gynecologic oncology
  Moore Kathleen N., etal A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study
  127:3, p. 456 - 461 2012
• Cancer research (Chicago, Ill.)
  Farley John H., etal Abstract CT-05: A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum
  72:8_Supplement, p. CT-05 - CT-05 2012
• Gynecologic Oncology
  Farley John H., etal American Society of Clinical Oncology 2012 Annual Meeting update: Summary of selected gynecologic cancer abstracts
  126:3, p. 319 - 324 2012
• Journal of reproductive medicine
  Larsen Wilma I, etal Risk factors for late postpartum preeclampsia
  57:1-2, p. 35 - 38 2012
• Clinical ovarian cancer and other gynecologic malignancies
  Boruta David, etal PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy
  4:2, p. 70 - 73 2011
• Gynecologic oncology
  Hamilton Chad A., etal The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study
  122:3, p. 521 - 526 2011
• Journal of clinical oncology
  Oliver K. E., etal The presence of racial disparities in histopathologic characteristics of uterine cancer in an equal-access environment
  29:15_suppl, p. 5094 - 5094 2011
• Gynecologic oncology
  Farley John, etal Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: A gynecologic oncology group study
  121:2, p. 395 - 401 2011
• Gynecologic oncology
  Farley John, etal Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study
  121:2, p. 303 - 308 2011
• Journal of clinical oncology
  Matei Daniela, etal Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
  29:1, p. 69 - 75 2011
• Journal of clinical oncology
  Farley J. H., etal Regulation of proliferation in endometrial carcinoma cell line by the epidermal growth factor receptor and estrogen receptor beta
  28:15_suppl, p. 5087 - 5087 2010
• Gynecologic oncology
  Farley John, etal Trial design for evaluation of novel targeted therapies
  116:2, p. 173 - 176 2010
• Oncology & Hematology Review (US)
  Oliver Kate E, etal Cisplatin plus Cetuximab in the Treatment of Recurrent and Persistent Cancers of the Cervix
  6, p. 45 2010
• International journal of gynecological cancer
  Na Young-Jeong, etal Ovarian Cancer Markers of Response
  19:11 Suppl 2, p. S21 - S29 2009
• Gynecologic oncology
  Farley John, etal Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study
  113:3, p. 341 - 347 2009
• Journal of clinical oncology
  Farley J. H., etal Phase II evaluation of cisplatin plus cetuximab in the treatment of recurrent and persistent cancers of the cervix: A limited access phase II study of the Gynecologic Oncology Group
  27:15_suppl, p. 5521 - 5521 2009
• Clinical ovarian cancer and other gynecologic malignancies
  Farley John, etal CON: Therapy for a Patient with Platinum–Resistant/Refractory Ovarian Cancer Should Not Be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay
  1:2, p. 99 - 103 2008
• Gynecologic oncology
  Hamilton Chad A., etal Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer
  111:3, p. 530 - 532 2008
• Journal of clinical oncology
  Farley J. H., etal Ethnicity and clinical outcome for advanced epithelial ovarian cancer patients treated by standard cisplatin/paclitaxel chemotherapy: A combined analysis of gynecologic oncology group clinical trials
  26:15_suppl, p. 5573 - 5573 2008
• The Surgical clinics of North America
  Stany Michael P., etal Complications of Gynecologic Surgery
  88:2, p. 343 - 359 2008
• Archives of gynecology and obstetrics
  Parente Lynn, etal Long-term impact of the women's health initiative on HRT
  277:3, p. 219 - 224 2008
• Cell Res
  Farley John, etal Genomic analysis of epithelial ovarian cancer
  18:5, p. 538 - 548 2008
• Disease markers
  Farley John, etal Cell cycle and related protein
  23:5-6, p. 433 - 443 2007
• Gynecologic oncology
  Farley John, etal Biomarkers and clinical trial design
  103:2, p. 3 - 5 2006
• Journal of reproductive medicine
  Farley John H, etal Far forward gynecologic care of the female soldier
  51:1, p. 31 - 35 2006
• Journal of clinical oncology
  Farley J. H., etal A randomized double-blind phase II evaluation of the cyclooxygenase-2 protein inhibitor celecoxib in treating severe dysplasia of the cervix
  23:16_suppl, p. 5106 - 5106 2005
• Current oncology reports
  Farley John H, etal Biologic directed therapies in gynecologic oncology
  5:6, p. 459 - 467 2003
• Gynecologic oncology
  Nycum L.R., etal The Role of p27 in Endometrial Carcinoma
  81:2, p. 242 - 246 2001
• Cancer
  Farley John H, etal Equal care ensures equal survival for African-American women with cervical carcinoma
  91:4, p. 869 - 873 2001
• Gynecologic oncology
  Farley John, etal Endocervical Cancer Is Associated with an Increase in the Ligands and Receptors for Transforming Growth Factor-β and a Contrasting Decrease in p27Kip1
  78:2, p. 113 - 122 2000
• Analytical and quantitative cytology and histology
  Farley J, etal Transferrin in normal and neoplastic endocervical tissues: distribution and receptor expression
  20:4, p. 238 - 249 1998
• Gynecologic oncology
  Teneriello Michael, etal Management of Advanced Ovarian Epithelial Cancer in the Renal Transplant Patient
  50:3, p. 374 - 378 1993
• Military medicine
  Farley John H., etal Chest Wall Tumors: Experience with 58 Patients
  156:8, p. 413 - 415 1991
• Military medicine
  Farley J. H, etal Chestwall tumors : experience with 58 patients
  156:8, p. 413 - 415 1991